U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Tuesday, June 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The interim analysis of the VOICE trial for Vafseo® revealed significant safety benefits for U.S. patients with anemia due to chronic kidney disease (CKD) on dialysis. The trial's primary investigator decided to halt the trial based on recommendations from the Independent Data Monitoring Committee and the Trial Steering Committee, highlighting the positive outcomes observed.
Price reaction · baseline $1.11 (2026-06-29 close) · hit pre-market · clean, no other AKBA news in the window
The trial demonstrated overwhelming statistical evidence.
The independent committees recommended stopping the trial due to positive results.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease
Full Press Release Details
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on
Frequently Asked Questions
What is Vafseo used for?
Vafseo is used for treating anemia in patients with chronic kidney disease (CKD) on dialysis.
What did the interim analysis of the VOICE trial reveal?
The interim analysis showed significant safety outcome benefits for patients treated with Vafseo.
Who recommended stopping the VOICE trial?
The trial was stopped based on recommendations from the Independent Data Monitoring Committee.
What is the dosing regimen for Vafseo in the trial?
The trial utilized a three-times-a-week (TIW) dosing regimen for Vafseo.